PEPN2011 - A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 12 months to 30 years old - patients with recurrent or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors are eligible - patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy - see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria

Exclusion Criteria:

- pregnant or breast-feeding women - patients who are currently receiving other anti-cancer agents - patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant - patients with primary brain tumors - patients who have received a solid organ transplant

Conditions & Interventions

Interventions:
Procedure: Biospecimen Collection, Procedure: Dual X-ray Absorptiometry, Drug: Tegavivint, Procedure: X-Ray Imaging
Conditions:
Cancer
Keywords:
recurrent cancer, refractory cancer, solid tumors

More Information

Description: This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating children, adolescents, and young adults with recurrent or refractory solid tumors, including lymphomas and desmoid tumors.
Study Contact: Allison Fullenkamp - fulle631@umn.edu
Principal Investigator: Robin Williams
Phase: PHASE1
IRB Number: SITE00001347